Valuation : Simulations Plus, Inc.

Market Cap 373M 321M 302M 276M 516M 35.19B 517M 3.57B 1.38B 18.06B 1.4B 1.37B 58.17B P/E 2026 *
43.9x
P/E 2027 * 40.3x
Enterprise Value 373M 321M 302M 276M 516M 35.19B 517M 3.57B 1.38B 18.06B 1.4B 1.37B 58.17B EV / Sales 2026 *
4.55x
EV / Sales 2027 * 4.32x
Free-Float
83.09%
Yield 2026 *
-
Yield 2027 * -
1 month-0.63%
3 months+8.97%
6 months+49.06%
1 week 15.8
Extreme 15.8
15.8
1 month 15.7
Extreme 15.7
15.9
Manager TitleAgeSince
Chief Executive Officer 67 2018-06-25
Director of Finance/CFO 63 2020-11-30
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 81 1996-07-16
Director/Board Member 58 2014-12-02
Chairman 76 2024-12-16
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 373M
-3.27%-0.58%+0.79%+23.65% 44.54B
-2.87%-5.99%-43.69%+130.49% 13.1B
-0.14%+0.97%-12.21%+86.15% 5.85B
-1.61%+2.37%+57.42% - 4.25B
+0.31%+6.91% - - 2.1B
-1.29%+3.90%+7.04%-41.73% 1.57B
+1.43%-4.31%-32.99% - 1.1B
+0.59%+1.58%+22.62%+147.60% 1.02B
-5.69%-5.39%+41.60%+43.96% 931M
Average -1.39%+0.01%+5.07%+65.02% 8.27B
Weighted average by Cap. -2.62%-0.71%-4.53%+50.63%

Financials

2026 *2027 *
Net sales 81.87M 70.45M 66.28M 60.55M 113M 7.73B 114M 783M 304M 3.97B 307M 301M 12.78B 86.26M 74.23M 69.84M 63.79M 119M 8.14B 120M 825M 320M 4.18B 324M 317M 13.46B
Net income 9.53M 8.2M 7.72M 7.05M 13.19M 900M 13.23M 91.21M 35.39M 462M 35.8M 35.02M 1.49B 10.18M 8.76M 8.24M 7.53M 14.09M 961M 14.12M 97.4M 37.8M 493M 38.23M 37.4M 1.59B
Net Debt - -
Logo Simulations Plus, Inc.
Simulations Plus, Inc. specializes in model-informed and artificial intelligence (AI)-accelerated drug development. The Company helps its clients by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through science-based software and consulting solutions. The Company’s segments include Software and Services. The Company's Software segment supports pharmaceutical research, development, and commercialization through simulation, modeling, and AI-driven prediction. Its main products include GastroPlus, ADMET Predictor, MonolixSuite, and others for disease modeling and training, as well as Pro-ficiency for clinical operations. Its Services segment includes advanced consulting services across the entire drug development lifecycle. Its scientists and engineers specialize in drug discovery, pharmacokinetics, pharmacodynamics, drug modeling, clinical trial data analysis, regulatory strategy, and medical communications.
Employees
-
Date Price Change
26-09-04 €15.80 0.00%
26-09-03 €15.80 0.00%
26-09-02 €15.80 0.00%
26-09-01 €15.80 0.00%
26-08-31 €15.80 0.00%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
5
Last Close Price
18.43USD
Average target price
17.25USD
Spread / Average Target
-6.40%

Quarterly revenue - Rate of surprise